| Literature DB >> 35091073 |
Abhijit Seetharam1, Priyanka Ghosh1, Ruben Prado1, Brian L Badman2.
Abstract
BACKGROUND: The COVID-19 (coronavirus disease 2019) pandemic has placed an increased burden on health care resources, with hospitals around the globe canceling or reducing most elective surgical cases during the initial period of the pandemic. Simultaneously, there has been an increased interest in performing outpatient total joint arthroplasty in an efficient manner while maintaining patient safety. The purpose of this study was to investigate trends in total shoulder arthroplasty (TSA) during the COVID-19 era with respect to outpatient surgery and postoperative complications.Entities:
Keywords: COVID-19; Total shoulder; arthroplasty; outcomes; outpatient; pandemic
Mesh:
Year: 2022 PMID: 35091073 PMCID: PMC8789381 DOI: 10.1016/j.jse.2021.12.031
Source DB: PubMed Journal: J Shoulder Elbow Surg ISSN: 1058-2746 Impact factor: 3.507
Patient demographic characteristics
| Pre–COVID-19 era | COVID-19 era | ||
|---|---|---|---|
| Patients, n | 297 | 270 | |
| Mean age, yr | 68.6 ± 8.8 | 68.3 ± 8.9 | .73 |
| Sex, n (%) | .24 | ||
| Male | 123 (41.4) | 126 (46.7) | |
| Female | 174 (58.6) | 144 (53.3) | |
| Average BMI | 32.3 ± 7.2 | 31.7 ± 7.3 | .44 |
| ASA score ≥ 3, n (%) | 165 (55.6) | 140 (51.9) | .45 |
| Diabetes, n (%) | 74 (26.7) | 67 (24.8) | .63 |
| Smoking status, n | |||
| Never | 180 | 154 | |
| Former | 100 | 92 | |
| Current | 15 | 20 | |
| CAD, n (%) | 47 (15.8) | 52 (19.3) | .32 |
| CHF, n (%) | 17 (5.7) | 8 (3.0) | .15 |
| Cognitive disorder, n (%) | 6 (2.0) | 6 (2.2) | >.99 |
| COPD, n (%) | 23 (7.9) | 26 (9.6) | .55 |
| OSA, n (%) | 59 (19.9) | 62 (22.9) | .42 |
| CKD, n (%) | 25 (8.4) | 32 (11.8) | .21 |
COVID, coronavirus disease; BMI, body mass index; ASA, American Society of Anesthesiologists; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; OSA, obstructive sleep apnea; CKD, chronic kidney disease.
Surgical encounter data
| Pre–COVID-19 era | COVID-19 era | ||
|---|---|---|---|
| Patients, n | 297 | 270 | |
| Outpatient cases, n (%) | 18 (6.1) | 86 (31.9) | <.0001 |
| Inpatient cases, n (%) | 279 (93.9) | 184 (68.1) | <.0001 |
| Anatomic TSA, n (%) | 120 (40.4) | 91 (33.7) | .32 |
| Reverse TSA, n (%) | 177 (59.6) | 179 (66.3) | .22 |
| Anesthesia | |||
| General and regional | 293 (98.7) | 261 (96.7) | .16 |
| General only | 4 (1.4) | 9 (3.3) |
COVID, coronavirus disease; TSA, total shoulder arthroplasty.
Statistically significant (P < .05).
Outcomes
| Pre–COVID-19 era | COVID-19 era | ||
|---|---|---|---|
| Average LOS, d | 1.37 | 0.81 | <.0001 |
| 90-d readmissions, n (%) | 20 (6.8) | 3 (1.1) | .0005 |
| 90-d ED visits, n (%) | 33 (11.1) | 11 (4.1) | .26 |
| 90-d infections, n (%) | 3 (1.0) | 2 (0.7) | .99 |
| 90-d VTE events, n (%) | 5 (1.7) | 2 (0.7) | .45 |
COVID, coronavirus disease; LOS, length of stay; ED, emergency department; VTE, venous thromboembolism.
Statistically significant (P < .05).
COVID-era subgroup analysis
| Inpatient | Outpatient | ||
|---|---|---|---|
| Patients, n | 184 | 86 | |
| Mean age, yr | 70.6 ± 8.1 | 64.1 ± 7.6 | <.001 |
| Sex, n (%) | .23 | ||
| Male | 86 (53.2) | 47 (54.7) | |
| Female | 98 (46.7) | 39 (45.3) | |
| BMI | 32.1 ± 7.4 | 31.1 ± 7.7 | .18 |
| ASA score ≥ 3, n (%) | 76 (54.2) | 64 (45.7) | .13 |
| Diabetes, n (%) | 37 (55.2) | 30 (44.8) | .23 |
| Smoking status, n | |||
| Never | 80 | 74 | |
| Former | 53 | 39 | |
| Current | 12 | 8 | |
| CAD, n (%) | 34 (18.5) | 18 (20.9) | .63 |
| CHF, n (%) | 5 (2.7) | 3 (3.5) | .73 |
| Cognitive disorder, n (%) | 4 (2.2) | 2 (2.3) | .94 |
| COPD, n (%) | 16 (8.7) | 10 (11.6) | .44 |
| OSA, n (%) | 38 (20.6) | 24 (27.9) | .18 |
| CKD, n (%) | 20 (10.8) | 12 (14.0) | .46 |
| 90-d readmissions, n (%) | 2 (1.1) | 1 (1.2) | .96 |
| 90-d ED visits, n (%) | 8 (4.3) | 4 (3.5) | .91 |
| 90-d VTE events, n (%) | 1 (0.5) | 1 (1.2) | .58 |
| 90-d infections, n (%) | 2 (1.1) | 0 (0) |
COVID, coronavirus disease; BMI, body mass index; ASA, American Society of Anesthesiologists; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; OSA, obstructive sleep apnea; CKD, chronic kidney disease; ED, emergency department; VTE, venous thromboembolism.
Statistically significant (P < .05).